Despite promising results have been obtained in preclinical models [10, 24], the phase III trial testing the dual IGF1R/IR inhibitor Linsitinib (OSI-906) in ACC showed a positive clinically response only in few patients [25]. This evidence concerns the gene IGF1R and adrenal cortex carcinoma.